1. Beier J, Kirsten A-M, Mróz R, Segarra R, Chuecos F, Caracta C, Garcia Gil E: Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD 2013, 10: 511-522. 10.3109/15412555.2013.814626
2. Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, Devillier P, Schnapp A: Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther 2010, 334: 53-62. 10.1124/jpet.110.167007
3. Bouyssou T, Hoenke C, Rudolf K, Lustenberger P, Pestel S, Sieger P, Lotz R, Heine C, Büttner FH, Schnapp A, Konetzki I: Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett 2010, 20: 1410-1414. 10.1016/j.bmcl.2009.12.087
4. European Medicines Agency: Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD). 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/08/WC500130880.pdf. Last updated 2012. Accessed 7 Aug 2013
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/08/WC500130880.pdf
.
5. Ferguson G, Feldman G, Hofbauer P, Hamilton A, Allen L, Korducki L, Sachs P: Lung function efficacy of olodaterol QD delivered via Respimat in COPD patients: Results from two 48-week studies [abstract]. Eur Respir J 2013 abstract 187, 42(Suppl 57):5s. abstract 187